BridgeBio Pharma, Inc. (BBIO) Stock Price, Financials & Summary

Price chart

Oct 7Oct 12Oct 15Oct 20Oct 23Oct 28Nov 2Nov 5

Key dataNov 5, 2026

Open$77.90

From 52W high−17.63%

Volume3.38M

Market cap$14.47B

P/E (TTM)—

P/S (TTM)15.3x

Div yield—

Key dataNov 5, 2026

Open

$77.90

From 52W high

−17.63%

Volume

3.38M

Market cap

$14.47B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−37.2x

P/E (TTM)

—

RSI (14)

67.3

MomentumView details →

1D Return

−4.65%

YTD Return

−0.05%

SummaryUpdated Sep 1, 2026

BridgeBio Pharma, Inc. (NASDAQ:BBIO) is a biotechnology company founded in 2015 and headquartered in Palo Alto, California. The company went public in June 2019 and focuses on discovering, developing, and delivering medicines for genetic diseases. BridgeBio operates with a unique decentralized model, creating subsidiary companies around specific therapeutic programs while maintaining a centralized platform for shared resources and expertise. The company has achieved its first major commercial success with the FDA approval and launch of Attruby (acoramidis) in 2024 for the treatment of transthyretin amyloidosis cardiomyopathy (ATTR-CM), marking a significant milestone in its evolution from a pure development-stage company to a commercial enterprise.

Ask drillr about BridgeBio Pharma, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−37.2x

EV/Sales

17.3x

P/S (TTM)

15.3x

P/B (TTM)

−8.7x

ProfitabilityView details →

Gross Margin

93.51%

Net Margin

−60.30%

EBITDA Margin

−46.60%

ROE (TTM)

34.30%

ROA (TTM)

−26.38%

Asset Turnover

0.56x

GrowthView details →

Revenue YoY

+167.27%

EPS YoY

+27.45%

FCF YoY

+37.11%

Revenue CAGR 3Y

+86.30%

EPS CAGR 3Y

−31.60%

EBITDA YoY

+34.95%

MomentumView details →

1D Return

−4.65%

YTD Return

−0.05%

1Y Return

+21.87%

RSI (14)

67.3

vs 50D SMA

+9.38%

vs 200D SMA

+5.13%

Capital & dividendView details →

Debt/Equity

−1.50x

Current Ratio

2.09x

Quick Ratio

2.03x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.42

EPS Surprise

22.54%

Beats (12Q)

3/12

Next Q EPS Est

−$0.58

Avg Surprise (4Q)

−16.58%

Rev Surprise

20.34%

Financials snapshotView financials →

Revenue (TTM)

945.54M

Net Income (TTM)

−570.21M

Op. CF (TTM)

−368.97M

Next earningsFeb 23, 2027 →

Latest newsMore news →

BridgeBio Pharma, Inc. reported a third-quarter loss of $0.42 per share, compared with a loss of $0.95 per share a year earlier.7d ago

Similar companies

Jazz Pharmaceuticals plcJAZZ 生物股份600201.SH Halozyme Therapeutics, Inc.HALO 神州细胞688520.SH Xcell Therapeutics, Inc.373110.KQ Metis Techbio-p07666.HK Find similar companies →

Latest newsMore news →

BridgeBio announced that two moderated posters and three posters on acoramidis and ATTR-CM, plus a BridgeBio-supported poster led by ABBOTT LABORATORIES, are scheduled for presentation at the American Heart Association, Inc. Scientific Sessions 2026.3d ago BridgeBio Pharma, Inc. reported a third-quarter loss of $0.42 per share, compared with a loss of $0.95 per share a year earlier.7d ago BridgeBio reported third-quarter 2026 total revenue of $353.2 million, including $253.2 million in U.S. Attruby net product revenue, and an operating loss of $11.6 million.7d ago